Literature DB >> 17324604

Iris pigment epithelial cell transplantation for degenerative retinal diseases.

Toshiaki Abe1, Madoka Yoshida, Yuki Yoshioka, Ryosuke Wakusawa, Yumi Tokita-Ishikawa, Haruka Seto, Makoto Tamai, Kohji Nishida.   

Abstract

The transplantation of different types of cells into the eye to treat retinal diseases has advanced in the past 20 years. One of the types of cells used for transplantation is the iris pigment epithelial (IPE) cell, because autologous IPE cells are easily obtained and their properties are similar to those of retinal pigment epithelial (RPE) cells and retinal cells. IPE cells are transplanted as; freshly isolated or cultured cells to replace defective or diseased RPE cells, genetically modified IPE cells for delivering target molecules to the retina or RPE, and retinal progenitor cells. IPE cells have also been transplanted for non-retinal disorders. The survival of the transplanted cells in the host is an important factor for the success of transplantation. Autologous IPE cells have been found in the transplanted subretinal space and were able to phagocytose rod outer segments even 6 months after transplantation. Allogeneic and xenogenic cells will not remain in the region longer than autologous cells. Allogenic cells transplanted into the subretinal space are rejected in humans. Thus, we have transplanted cultured autologous IPE cells in 56 patients with age-related macular degeneration. The long-term results (more than 2 years with a maximum of 8 years) showed that the visual acuity (VA) was significantly improved over the pre-transplantation VA, although a slight decrease of VA was observed 2 weeks after the transplantation. One patient showed a vasculitis-like lesion. IPE cells that were transduced with neurotrophic factors by plasmid or viral vectors have also been transplanted in animals. We have transduced several neurotrophic factor genes into IPE cells with a plasmid vector, adeno-associated virus, or adenovirus. Transplantation of these transduced IPE cells into the subretinal space rescued photoreceptor cells from several types of photoreceptor toxicities. In addition, transduction of a gene into the IPE cells suppressed the systemic dissemination of the viral genome. The neuroprotective effects of the IPE cells were different for the different types of neurotrophic factor, and some of the neurotrophic factors may enhance systemic immune reaction after transplantation. IPE cells have also been used as retinal progenital cells because they originate from the same cell lines that give rise to the neural retina and RPE cells. The transduction of the photoreceptor-related homeobox gene was reported to induce photoreceptor phenotypes in IPE cells. Furthermore, transplantations of IPE cells have been performed to treat central nervous system disorders. In this review, we summarize recent progress on IPE transplantation.

Entities:  

Mesh:

Year:  2007        PMID: 17324604     DOI: 10.1016/j.preteyeres.2007.01.003

Source DB:  PubMed          Journal:  Prog Retin Eye Res        ISSN: 1350-9462            Impact factor:   21.198


  17 in total

Review 1.  Cell replacement and visual restoration by retinal sheet transplants.

Authors:  Magdalene J Seiler; Robert B Aramant
Journal:  Prog Retin Eye Res       Date:  2012-07-05       Impact factor: 21.198

Review 2.  A tissue-engineered approach towards retinal repair: scaffolds for cell transplantation to the subretinal space.

Authors:  Sara Royce Hynes; Erin B Lavik
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-02-19       Impact factor: 3.117

Review 3.  Retinal pigment epithelium transplantation: concepts, challenges, and future prospects.

Authors:  P Alexander; H A J Thomson; A J Luff; A J Lotery
Journal:  Eye (Lond)       Date:  2015-06-05       Impact factor: 3.775

Review 4.  Induced pluripotent stem cell therapies for geographic atrophy of age-related macular degeneration.

Authors:  Hongjun Du; Siok Lam Lim; Seanna Grob; Kang Zhang
Journal:  Semin Ophthalmol       Date:  2011-05       Impact factor: 1.975

5.  Implantation and explantation of an active epiretinal visual prosthesis: 2-year follow-up data from the EPIRET3 prospective clinical trial.

Authors:  J Menzel-Severing; T Laube; C Brockmann; N Bornfeld; W Mokwa; B Mazinani; P Walter; G Roessler
Journal:  Eye (Lond)       Date:  2012-03-16       Impact factor: 3.775

6.  Biobanking of Human Retinas: The Next Big Leap for Eye Banks?

Authors:  Zala Lužnik; Mohit Parekh; Marina Bertolin; Carlo Griffoni; Diego Ponzin; Stefano Ferrari
Journal:  Stem Cells Transl Med       Date:  2015-06-01       Impact factor: 6.940

Review 7.  Recent progress on tissue-resident adult stem cell biology and their therapeutic implications.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  Stem Cell Rev       Date:  2008       Impact factor: 5.739

8.  A novel mutation (967-970+2)delAAAGGT in the choroideremia gene found in a Japanese family and related clinical findings.

Authors:  Yutaka Iino; Takuro Fujimaki; Keiko Fujiki; Akira Murakami
Journal:  Jpn J Ophthalmol       Date:  2008-09-05       Impact factor: 2.447

9.  Molecular analysis of the choroideremia gene related clinical findings in two families with choroideremia.

Authors:  Ying Lin; Xialin Liu; Lixia Luo; Bo Qu; Shuhong Jiang; Huiqin Yang; Xuanwei Liang; Shaobi Ye; Yizhi Liu
Journal:  Mol Vis       Date:  2011-09-30       Impact factor: 2.367

10.  Whole-exome sequencing reveals a novel CHM gene mutation in a family with choroideremia initially diagnosed as retinitis pigmentosa.

Authors:  Hui Guo; Jisheng Li; Fei Gao; Jiangxia Li; Xinyi Wu; Qiji Liu
Journal:  BMC Ophthalmol       Date:  2015-07-28       Impact factor: 2.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.